Subcellular MLH1 protein as first in class biomarker for CDK4/6 response in endocrine resistant ER+/HER2-breast cancer

被引：0
|
作者：
Mazumder, Aloran
Oropeza, Elena
Punturi, Nindo
Haricharan, Svasti
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-5129
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5129
引用
收藏
页数：2
相关论文
共 50 条
  • [21] The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2-Breast Cancer
    Oshi, Masanori
    Takahashi, Hideo
    Tokumaru, Yoshihisa
    Yan, Li
    Rashid, Omar M.
    Nagahashi, Masayuki
    Matsuyama, Ryusei
    Endo, Itaru
    Takabe, Kazuaki
    [J]. CELLS, 2020, 9 (07) : 1 - 19
  • [22] Targeting of endocrine therapy-induced estrogen-receptor/HER2-cross-talk in circulating tumor cells from metastatic ER+/HER2-breast cancer: Implications for treatment of ER+/HER2-breast cancer
    Thaler, S.
    Rosswag, S.
    Pantel, K.
    Sleeman, J. P.
    Schmidt, M.
    Cotarelo, C. L.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [23] SPEN is a biomarker for CDK4/6 inhibitor resistance in patients with metastatic hormone receptor positive (HR+)/HER2-breast cancer
    Van Geelen, Courtney T.
    Teo, Zhi Ling
    Savas, Peter
    Luen, Stephen J.
    Clarke, Kylie A.
    Sant, Sneha
    Cowley, Karla J.
    Caramia, Franco
    Simpson, Kaylene J.
    Andre, Fabrice
    Dawson, Sarah-Jane
    Pearson, Richard
    Loi, Sherene
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [24] Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
    Luigi Formisano
    Yao Lu
    Alberto Servetto
    Ariella B. Hanker
    Valerie M. Jansen
    Joshua A. Bauer
    Dhivya R. Sudhan
    Angel L. Guerrero-Zotano
    Sarah Croessmann
    Yan Guo
    Paula Gonzalez Ericsson
    Kyung-min Lee
    Mellissa J. Nixon
    Luis J. Schwarz
    Melinda E. Sanders
    Teresa C. Dugger
    Marcelo Rocha Cruz
    Amir Behdad
    Massimo Cristofanilli
    Aditya Bardia
    Joyce O’Shaughnessy
    Rebecca J. Nagy
    Richard B. Lanman
    Nadia Solovieff
    Wei He
    Michelle Miller
    Fei Su
    Yu Shyr
    Ingrid A. Mayer
    Justin M. Balko
    Carlos L. Arteaga
    [J]. Nature Communications, 10
  • [25] Optimizing CDK4/6 inhibitors in advanced HR+/HER2-breast cancer: A personalized approach
    Fontanella, Caterina
    Giorgi, Carlo Alberto
    Russo, Stefania
    Angelini, Silvia
    Nicolardi, Linda
    Giarratano, Tommaso
    Frezzini, Simona
    Pestrin, Marta
    Palleschi, Dario
    Bolzonello, Silvia
    Parolin, Veronica
    Haspinger, Eva R.
    De Rossi, Costanza
    Greco, Filippo
    Gerratana, Lorenzo
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 180
  • [26] Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer
    Stefania Belli
    Daniela Esposito
    Alessandra Allotta
    Alberto Servetto
    Paola Ciciola
    Ada Pesapane
    Claudia M. Ascione
    Fabiana Napolitano
    Concetta Di Mauro
    Elena Vigliar
    Antonino Iaccarino
    Carmine De Angelis
    Roberto Bianco
    Luigi Formisano
    [J]. npj Breast Cancer, 9
  • [27] Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer
    Belli, Stefania
    Esposito, Daniela
    Allotta, Alessandra
    Servetto, Alberto
    Ciciola, Paola
    Pesapane, Ada
    Ascione, Claudia M.
    Napolitano, Fabiana
    Di Mauro, Concetta
    Vigliar, Elena
    Iaccarino, Antonino
    De Angelis, Carmine
    Bianco, Roberto
    Formisano, Luigi
    [J]. NPJ BREAST CANCER, 2023, 9 (01)
  • [28] Response of persistent metastatic ER+/Her2-breast cancer treated with fulvestrant plus enzalutamide
    Richer, Jennifer
    Spoelstra, Nicole
    Winchester, Alyse
    Wulfkuhlue, Julia
    Gallagher, Rosa
    Sams, Sharon
    Vidal, Gregory
    Kabos, Peter
    Diamond, Jennifer
    Shagisultanova, Elena
    Afghahi, Anosheh
    Mayordomo, Jose
    McSpadded, Tessa
    Crawford, Gloria
    Borges, Virginia
    Gao, Dexiang
    Petricoin, Emanuel
    Elias, Anthony
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [29] CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer: Clinico-Pathological Analysis for Determinants of Response
    Maruthi, Vijaya Kadam
    Schultz, Emily
    Knudsen, Erik
    Witkiewicz, Agnieszka
    Hamilton, Deanna
    [J]. MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 136 - 138
  • [30] CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer: Clinico-Pathological Analysis for Determinants of Response
    Maruthi, Vijaya Kadam
    Schultz, Emily
    Knudsen, Erik
    Witkiewicz, Agnieszka
    Hamilton, Deanna
    [J]. LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 136 - 138
12345